SEI Investments’s Atea Pharmaceuticals AVIR Stock Holding History

SEI Investments’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$841K	Buy	+156,384	New	+$718K	﹤0.01%	2436
2022 Q1	–	Sell	-54,079	Closed	-$483K	–	2578
2021 Q4	$483K	Buy	+54,079	New	+$843K	﹤0.01%	2120

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SEI Investments's AVIR Position: Q1 2026 in Review

SEI Investments opened a new position in Atea Pharmaceuticals (AVIR) in Q1 2026: 156,384 shares worth $841K. The stake represents ﹤0.01% of the portfolio and ranks #2436 among its holdings. This is a return to the name: SEI Investments previously reported a position in AVIR as recently as Q4 2021.

SEI Investments first reported a position in AVIR in Q4 2021 and has held it in 2 quarters since. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

SEI Investments held 156,384 shares of Atea Pharmaceuticals worth $841K as of Q1 2026.
Atea Pharmaceuticals was a new SEI Investments position in Q1 2026.
Atea Pharmaceuticals made up ﹤0.01% of SEI Investments's portfolio in Q1 2026, its #2436 holding.
SEI Investments first reported a position in Atea Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.